IDEXX Laboratories, Inc. vs Cloudflare Inc — how do they compare? IDEXX Laboratories, Inc. trades at $512.76 (market cap $40.43B), while Cloudflare Inc trades at $346.5 (market cap $121.74B). The key difference: Cloudflare Inc is far larger — about 3× IDEXX Laboratories, Inc.'s market cap, and Cloudflare Inc is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Cloudflare Inc for 61 Days on average.
| IDXX | NET | |
|---|---|---|
Market Cap | $40.43B | $121.74B |
Volume | 692,164 | 2,433,002 |
Sector | Health | Technology |
52-Week High | $766.68 | $359.60 |
52-Week Low | $504.70 | $160.16 |
Typical Hold Time | 46 Days | 61 Days |
Enterprise Value | $41.32B | $121.11B |
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $506.67, down 1.7% on the day, with technical indicators showing bearish momentum despite strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $4.27 exceeding expectations of $3.94. Recent developments include the acquisition of CoVetAI to enhance veterinary workflow intelligence and expansion of diagnostic testing platforms internationally. Revenue growth remains robust at $4.3 billion for 2025, with net income margins exceeding 25%.
The stock presents a compelling growth story with strong profitability metrics and analyst consensus pointing to significant upside potential (average price target $665). However, current technical weakness and premium valuations (P/E 36.06) create near-term headwinds. Key risks include foreign exchange pressures and potential slowdown in U.S. veterinary visits, while institutional ownership trends show mixed positioning among major funds.
Cloudflare (NET) trades at $342.82, down 3.44% on the day, as the stock consolidates near recent highs. The company continues to demonstrate strong revenue growth with $2.17 billion in 2025 sales, though profitability remains challenged with a -8.21% net margin. Recent technical indicators show a bullish trend with the stock trading above key support levels, while analyst sentiment remains overwhelmingly positive with 71% buy ratings. The company's recent product launches including Cloudflare Basin and strategic partnerships with Deutsche Telekom highlight ongoing innovation in the connectivity cloud space.
Cloudflare presents a growth story with expanding enterprise adoption but faces valuation concerns at current levels. The stock's premium multiples (P/S 47.88) require continued execution against strong revenue growth targets. Key risks include persistent profitability challenges and competitive pressures in the cloud security market, while catalysts include AI-driven security demand and platform consolidation opportunities.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →Cloudflare is a software company based in San Francisco, California, that offers security and web performance offerings by utilizing a distributed, serverless content delivery network, or CDN. The firm's edge computing platform, Workers, leverages this network by providing clients the ability to deploy, and execute code without maintaining servers.
Read more on NET →